We deliver market intelligence combining stock research, financial news, and earnings summaries to support data-driven investment decisions.
Supernus Pharmaceuticals Inc. (SUPN) is a mid-cap specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. As of current trading on 2026-04-18, SUPN shares are priced at $51.39, representing a 4.41% gain from the previous closing level. This analysis outlines key market context, technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available as of the publication da
Supernus Pharmaceuticals (SUPN) Stock DCF Valuation (Creeps Higher) 2026-04-18 - Wave Equality
SUPN - Stock Analysis
3009 Comments
656 Likes
1
Zendy
Registered User
2 hours ago
{协议答案}
👍 127
Reply
2
Jakobe
Active Reader
5 hours ago
{协议答案}
👍 270
Reply
3
Ricketa
Senior Contributor
1 day ago
{协议答案}
👍 278
Reply
4
Cashmier
Insight Reader
1 day ago
{协议答案}
👍 155
Reply
5
Danitza
Active Reader
2 days ago
{协议答案}
👍 180
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.